2015
DOI: 10.1517/17425247.2016.1112374
|View full text |Cite
|
Sign up to set email alerts
|

Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment

Abstract: To develop a successful HA-based nanomedicine, it has to be prepared without significant deterioration of intrinsic property of HA. The chemical modification of HA with drugs or hydrophobic moieties may reduce the binding affinity of HA to the receptors. In addition, since the HA-based nanomedicines tend to accumulate in the liver after their systemic administration, new strategies to overcome this issue have to be developed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
47
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 87 publications
(48 citation statements)
references
References 105 publications
1
47
0
Order By: Relevance
“…82 In recent years, HA has also been investigated as a targeting moiety of NTDDS for cancer therapy because of the overexpression of CD44 in various cancer cells. [84][85][86] A recent study demonstrated that HA could actively mediate NPs into hepatoma cells. For instance, the surface modification of superparamagnetic iron oxide (SPIO) NPs was performed by conjugating HA, and the in vitro magnetic resonance (MR) imaging of CD44 + HepG2 cells and in vivo MR imaging of mice HepG2 cell-bearing tumor xenografts confirmed the high efficiency and targeting of liver carcinoma.…”
Section: Polysaccharidesmentioning
confidence: 99%
“…82 In recent years, HA has also been investigated as a targeting moiety of NTDDS for cancer therapy because of the overexpression of CD44 in various cancer cells. [84][85][86] A recent study demonstrated that HA could actively mediate NPs into hepatoma cells. For instance, the surface modification of superparamagnetic iron oxide (SPIO) NPs was performed by conjugating HA, and the in vitro magnetic resonance (MR) imaging of CD44 + HepG2 cells and in vivo MR imaging of mice HepG2 cell-bearing tumor xenografts confirmed the high efficiency and targeting of liver carcinoma.…”
Section: Polysaccharidesmentioning
confidence: 99%
“…The part of CD44 called HABD is responsible for binding with hyaluronan [ 13 ]. Hyaluronan hexasaccharide (2.4 kDa) seems to be of the optimum size for binding to the CD44 receptor [ 14 , 15 ]. However, shorter fragments of between about 3 and 5 disaccharide units (1.2–2.0 kDa) also have receptor binding capacity [ 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…In cancer therapy, the tumor microenvironment is considered an ideal trigger for the selective release of anticancer drugs in tumor tissues and within tumor cells (Duncan, 2003 ; Cabane et al, 2012 ; Liu et al, 2013 ; Mura et al, 2013 ; Chang et al, 2016 ). The extracellular regions around normal tissues and blood have a constant pH of 7.4, but the extracellular pH region of tumors ranges from 6.0 to 6.5 (Duncan and Kopeček, 1984 ; Rao et al, 2016 ; Kocak et al, 2017 ). This distinction in pH between normal and tumor tissues in endosomal and lysosomal compartments can be used as an internal stimulus for triggered drug release for chemotherapy (Bae et al, 2003 ; Cairns et al, 2011 ; Liu et al, 2013 ).…”
Section: Endogenous Stimuli-responsive Polymersmentioning
confidence: 99%